This site is intended for healthcare professionals

New data on Lenvima + Keytruda versus sunitinib from Phase III KEYNOTE 581 study in first-line treatment for patients with advanced renal cell carcinoma. Eisai + Merck Inc.

Read time: 2 mins
Last updated:28th Jun 2021
Published:8th Jun 2021
Eisai Co., Ltd. and Merck & Co., Inc., announced new investigational data from the pivotal Phase III CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor plus Keytruda, the anti-PD-1 therapy from Merck Inc., and Lenvima plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest